Drug interactions
Insulin glargine-lixisenatide + Linagliptin
Severity: Moderate
Insulin glargine-lixisenatide and Linagliptin: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Combining a DPP-4 inhibitor with insulin and a GLP-1 receptor agonist adds glucose-lowering effect and may raise hypoglycemia risk. The combination also duplicates incretin-based therapy with little added benefit.
What this interaction means in plain words
Insulin glargine-lixisenatide and Linagliptin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Insulin glargine-lixisenatide belongs to Endocrine; Linagliptin belongs to Endocrine.
Why it happens
Duplicate incretin pathway enhancement plus additive insulin effect.
What to do
Avoid combining a DPP-4 inhibitor with a GLP-1 receptor agonist where possible. If continued, monitor blood glucose and reduce insulin if hypoglycemia occurs.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Insulin glargine-lixisenatide and Linagliptin, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Insulin glargine-lixisenatide
- Albiglutide + Insulin glargine-lixisenatide Major
- Chlorpropamide + Insulin glargine-lixisenatide Major
- Dulaglutide + Insulin glargine-lixisenatide Major
- Ethanol + Insulin glargine-lixisenatide Major
- Exenatide injectable + Insulin glargine-lixisenatide Major
- Glimepiride + Insulin glargine-lixisenatide Major
Other interactions of Linagliptin
- Alogliptin-pioglitazone + Linagliptin Moderate
- Amlodipine-benazepril + Linagliptin Moderate
- Amobarbital + Linagliptin Moderate
- Apalutamide + Linagliptin Moderate
- Benazepril + Linagliptin Moderate
- Bexarotene + Linagliptin Moderate
Frequently asked questions
Can I take Insulin glargine-lixisenatide with Linagliptin?
MediHelp rates the interaction as moderate. Insulin glargine-lixisenatide and Linagliptin can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Combining a DPP-4 inhibitor with insulin and a GLP-1 receptor agonist adds glucose-lowering effect and may raise hypoglycemia risk. The combination also duplicates incretin-based therapy with little added benefit.
How serious is the interaction between Insulin glargine-lixisenatide and Linagliptin?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid combining a DPP-4 inhibitor with a GLP-1 receptor agonist where possible. If continued, monitor blood glucose and reduce insulin if hypoglycemia occurs.
What other medicines interact with Insulin glargine-lixisenatide?
MediHelp also lists interactions of Insulin glargine-lixisenatide with, for example, Albiglutide, Chlorpropamide, Dulaglutide. The full list is on the Insulin glargine-lixisenatide page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
